Vertex Pharmaceuticals VRTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.34B— | $3.95B— | —— | —— | —— | ||
| $217.3M+7.5% | $209.8M+1.3% | $200.6M-8.7% | $199.8M-4.2% | $202.1M+3.1% | ||
| $686.2M+2.0% | $685.9M-1.8% | $696.1M-5.8% | $685.8M0.0% | $672.7M+3.4% | ||
| $137.9M— | $347.3M— | —— | —— | —— | ||
| $454.8M-24.7% | $524.2M+1.3% | $594.3M+35.1% | $645.7M+82.0% | $604.3M+88.6% | ||
| $46.2M-38.9% | $36.8M-25.7% | $6.9M-87.0% | $108.3M+3,088% | $75.6M+32.5% | ||
| $149.6M— | $148.5M— | —— | —— | —— | ||
| $4.24B+233% | $3.63B+235% | $3.01B+229% | $1.65B+274% | -$3.18B-181% | ||
| $530.3M+96.4% | $437.6M+47.0% | $380.8M+44.7% | $346.7M+46.8% | $270M+19.1% | ||
| $7.26B+11.9% | $6.4B-14.0% | $7.32B+16.9% | $7.36B+39.2% | $6.49B+42.0% | ||
| -$1.32B+21.8% | -$945.4M+74.9% | -$1.48B+61.4% | -$1.71B+52.6% | -$1.69B+51.0% | ||
| $1.93B+31.0% | $2.02B+71.4% | $2.31B+154% | $1.54B+115% | $1.47B+246% | ||
| $327.9M-25.8% | $369.9M-8.7% | $374.7M-6.5% | $367.4M-0.8% | $442M+50.9% | ||
| -$2.12B-16.6% | -$2.26B-51.3% | -$2.58B-111% | -$1.81B-80.7% | -$1.82B-183% | ||
| $24.2M+591% | $95M+323% | $40.4M+25.9% | $63.2M+579% | $3.5M+600% | ||
| $853.7M— | $549.8M— | -$266.1M— | —— | —— | ||
| $12.9M-44.4% | $12.4M-59.3% | $12.1M-68.4% | $17M-58.3% | $23.2M-44.8% | ||
| $0-100% | $379M— | $379M— | $379M— | $379M— | ||
| -$94.5M— | -$116.9M— | —— | —— | —— | ||
| $194.5M— | $396M— | $310M— | —— | —— | ||
| -$75.9M+0.8% | -$120.1M-13,244% | -$113.4M-334% | -$155M-240% | -$76.5M-176% | ||
| $20.2M-65.9% | $25.5M-52.8% | $40.5M+31.3% | $48.6M+104% | $59.3M+257% | ||
| $6.47B+20.0% | $5.9B+32.1% | $6.27B+94.4% | $6.05B+148% | $5.39B+260% | ||
| $138M+20.6% | $127.7M+11.4% | $108M-14.8% | $108.5M-18.8% | $114.4M-16.7% | ||
| $3.8M+72.7% | $3.7M-40.3% | $3.5M-39.1% | $3.3M-44.5% | $2.2M-64.2% | ||
| $1.46B+18.9% | $1.57B+44.8% | $1.45B-7.6% | $1.25B-21.5% | $1.23B-22.6% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $3.71B+208% | $3.19B+207% | $2.65B+202% | $1.31B+211% | -$3.44B-193% | ||
| $3.71B+208% | $3.19B+207% | $2.65B+202% | $1.31B+211% | -$3.44B-193% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
